CTC Cell

The TRACE Platform is a next-generation liquid biopsy solution designed for the fully automated isolation, identification, and analysis of circulating tumor cells (CTCs) from whole blood. Using proprietary continuous centrifugal microfluidic technology and lossless immunocytochemistry staining, the system captures CTCs regardless of cell size or surface markers, overcoming the key limitations of existing FDA-approved technologies. With high recovery rates, full automation, integrated AI-based image analysis, and compatibility with downstream molecular and drug-response testing, the TRACE Platform enables real-time cancer monitoring, precision diagnostics, companion diagnostics, and drug development applications.

Please Log In to access Additional Details and documents …

• Marker-free and size-independent CTC isolation:
  Captures the full spectrum of CTCs regardless of surface markers (e.g., EpCAM) or cell size, eliminating false negatives associated with marker-based or size-based systems.
  
  

• Continuous centrifugal microfluidic (CCM) core technology:
  Proprietary negative depletion-based separation efficiently removes non-tumor cells while preserving tumor cells with high purity and recovery.
  
  

• Fully automated end-to-end workflow:
  Complete automation from whole-blood separation through staining, imaging, AI detection, and CTC picking for maximum reproducibility and high throughput.
  
  

• Rapid turnaround time:
  Delivers complete CTC isolation and analysis within approximately 1.5 hours.
  
  

• Lossless cell staining via HypICC platform:
  Hydrogel pellicle immunocytochemistry minimizes cell loss during staining and preserves true cellular morphology.
  
  

• AI-powered real-time CTC detection:
  Lightweight knowledge-distillation AI model enables high-speed real-time image analysis, suitable for on-device deployment with reduced cloud dependency.
  
  

• High recovery rate and clinical sensitivity:
  Demonstrates significantly higher CTC detection rates compared with leading FDA-approved competitors in early breast cancer and cell-line validation studies.
  
  

• Minimal cellular stress and viable CTC culture:
  Preserves cell integrity and viability, enabling successful ex vivo CTC culture for downstream research and functional testing.
  
  

• Integrated multi-omics capability:
  Supports downstream genomic, proteomic, and morphological analysis from isolated CTCs for translational research and precision oncology.
  
  

• Clinical application areas:
  Companion diagnostics, minimal residual disease (MRD) monitoring, early cancer detection, therapeutic response prediction, drug efficacy monitoring, and relapse surveillance.
  
  

• Drug development and biomarker discovery:
  Enables patient stratification, biomarker discovery, and pharmacodynamic monitoring using live tumor cell data rather than static tissue snapshots.